Titrating-Dose of Lonafarnib in Combination With Ritonavir

Exclusion Criteria

• •1. Previous use of lonafarnib
• •2. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV)
• •3. Active jaundice defined by total bilirubin level \>2.0 mg/dL and known not to have Gilbert's disease
• •4. Decompensated liver disease or cirrhosis, history of bleeding esophageal varices, ascites, or hepatic encephalopathy
• •5. Serum creatinine concentration ≥1.5 times upper limit of normal (ULN)
• •6. Evidence of another form of viral hepatitis (not including hepatitis B virus or HCV) or another form of liver disease
• •7. Evidence of hepatocellular carcinoma
• •8. Use of alfa interferon, either interferon alfa-2a or interferon alfa-2b, or peginterferon alfa-2a within 2 months before the start of screening
• •9. Concomitant use of any of the following:
• •1. Medications or foods that are known moderate or strong inducers or inhibitors of CYP3A4 or CYP2C19
• •2. Drugs known to prolong the PR interval or QT interval of the electrocardiogram
• •3. Receipt of systemic immunosuppressive therapy within the 3 months before start of screening
• •4. Statins, due to inhibition of mevalonate synthesis, which reduces protein prenylation
• •5. Medications contraindicated in the prescribing information for ritonavir